Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$8 Mln
Revenue (TTM)
$0 Mln
Net Profit (TTM)
$0 Mln
ROE
-1 %
ROCE
-- %
P/E Ratio
--
P/B Ratio
0.6
Industry P/E
--
EV/EBITDA
-0.6
Div. Yield
0 %
Debt to Equity
--
Book Value
$12835117
EPS
$-7.2
Face value
--
Shares outstanding
2,282,371
CFO
$-19.60 Mln
EBITDA
$-23.39 Mln
Net Profit
$-26.37 Mln
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Aclarion Inc (ACON)
| -22.4 | 30.3 | -22.4 | -68.4 | -99.5 | -- | -- |
|
BSE Sensex
| -13.4 | -9.8 | -13.9 | -3.6 | 7.5 | 7.9 | 11.2 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2025
|
2024
|
2023
|
|---|---|---|---|
|
Aclarion Inc (ACON)
| -100.0 | -95.4 | -65.5 |
|
S&P Small-Cap 600
| 4.0 | 7.0 | 13.9 |
|
BSE Sensex
| 9.1 | 8.1 | 18.7 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Aclarion Inc (ACON)
|
3.6 | 8.2 | 0.1 | -7.2 | -9,689.0 | -0 | -- | 0.6 |
| 61.0 | 8,546.2 | 1,091.0 | 202.3 | 31.6 | 31.3 | 38.1 | 15.0 | |
| 66.7 | 8,218.7 | 88.0 | -785.0 | -808.1 | 197.5 | -- | 60.5 | |
| 43.9 | 11,764.8 | 2,320.1 | 782.6 | 39.0 | 35.5 | 15.8 | 5.3 | |
| 93.8 | 12,307.7 | 982.0 | -416.3 | -42.1 | 348.4 | -- | 60.9 | |
| 64.5 | 7,640.4 | 1,396.6 | 316.9 | 59.8 | 153.6 | 25.2 | 156.5 | |
| 546.9 | 12,545.6 | 958.4 | -288.3 | -27.8 | -42.5 | -- | 20.8 | |
| 498.3 | 14,143.5 | 2,530.2 | 451.1 | 21.3 | 70.2 | 32.7 | 30.2 | |
| 105.4 | 8,288.6 | 0.0 | -425.4 | -- | -36.7 | -- | 6.7 | |
| 310.4 | 8,644.3 | 0.0 | -303.3 | -- | -45.8 | -- | 10.1 |
Aclarion, Inc. operates as a healthcare technology company in the United States. It uses magnetic resonance spectroscopy (MRS) and proprietary biomarkers to optimize clinical treatments. The company develops NOCISCAN, which uses MRS capabilities to... non-invasively analyze the chemical makeup of intervertebral discs in the spine. It also provides NOCISCAN MRS Exam Protocol, a custom software protocol for using commercially available MRS pulse sequences in scanning intervertebral discs which extends the time of a standard lumbar MRI exam; and imaging data transfer products, including AMBRA Healthcare, a data transfer platform. In addition, the company offers The NOCISCAN Post-Processor Suite comprising NOCICALC, a Class I medical device that receives the raw un-processed NOCISCAN MRS exam data and post-processes that raw data into final spectra, and performs various degenerative pain biomarker calculations from those spectra, for each disc examined; and NOCIGRAM, which further processes the NOCICALC results into individual NOCISCORES, on a 0-10 scale, that represent the different relative levels of degenerative pain biomarkers the various discs examined in the patient. The company was formerly known as Nocimed, Inc. and changed its name to Aclarion, Inc. in December 2021. Aclarion, Inc. was incorporated in 2008 and is based in Broomfield, Colorado. Read more
Executive Chairman
Dr. Jeffrey John Thramann M.D.
Executive Chairman
Dr. Jeffrey John Thramann M.D.
Headquarters
Broomfield, CO
Website
Our rating system has guided millions of investors in the past 20 years.
The share price of Aclarion Inc (ACON) is $3.57 (NASDAQ) as of 02-Apr-2026 19:59 EDT. Aclarion Inc (ACON) has given a return of -99.53% in the last 3 years.
Since, TTM earnings of Aclarion Inc (ACON) is negative, P/E ratio is not available.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2025
|
-0.64
|
0.00
|
|
2024
|
--
|
--
|
|
2023
|
--
|
--
|
|
2022
|
--
|
--
|
|
2021
|
--
|
--
|
The 52-week high and low of Aclarion Inc (ACON) are Rs 13.69 and Rs 2.34 as of 05-Apr-2026.
Aclarion Inc (ACON) has a market capitalisation of $ 8 Mln as on 02-Apr-2026. As per SEBI classification, it is a Small Cap company.
Before investing in Aclarion Inc (ACON), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
$0.16
(
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.